Biontech SE
BNTX99.850USD
+1.000+1.01%
收盤 01/09, 16:00（美東）報價延遲15分鐘
24.01B總市值
虧損本益比TTM
關於 Biontech SE 公司
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Biontech SE簡介
公司代碼BNTX
公司名稱Biontech SE
上市日期Oct 10, 2019
CEOSahin (Ugur)
員工數量6772
證券類型Depository Receipt
年結日Oct 10
公司地址An der Goldgrube 12
城市MAINZ
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Germany
郵編55131
電話4949613190840
網址https://www.biontech.com/
公司代碼BNTX
上市日期Oct 10, 2019
CEOSahin (Ugur)
Biontech SE公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+12755.00%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
+790.00%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mr. Michael Motschmann
Mr. Michael Motschmann
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Michael Horowicz
Mr. Michael Horowicz
Director, Investor Relations
Director, Investor Relations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+12755.00%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
+790.00%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
收入明細
單位: USD更新時間: 3月12日 週三
單位: USD更新時間: 3月12日 週三
FY2019
FY2018
FY2017
業務USD
名稱
營收
佔比
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
由於公司未披露，未能獲取相關數據
業務
地區
業務USD
名稱
營收
佔比
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
股東統計
更新時間: 11月15日 週六
更新時間: 11月15日 週六
持股股東
股東類型
持股股東
持股股東
佔比
AT Impf GmbH
39.32%
Medine GmbH
15.49%
Baillie Gifford & Co.
3.04%
Fidelity Management & Research Company LLC
1.92%
T. Rowe Price Investment Management, Inc.
1.87%
其他
38.36%
持股股東
持股股東
佔比
AT Impf GmbH
39.32%
Medine GmbH
15.49%
Baillie Gifford & Co.
3.04%
Fidelity Management & Research Company LLC
1.92%
T. Rowe Price Investment Management, Inc.
1.87%
其他
38.36%
股東類型
持股股東
佔比
Corporation
59.74%
Investment Advisor
15.63%
Investment Advisor/Hedge Fund
3.83%
Individual Investor
2.11%
Research Firm
1.19%
Hedge Fund
1.05%
Sovereign Wealth Fund
0.63%
Bank and Trust
0.22%
Pension Fund
0.18%
其他
15.43%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
774
54.93M
21.75%
-6.01M
2025Q3
808
54.84M
25.69%
-1.45M
2025Q2
821
56.21M
24.34%
+2.26M
2025Q1
832
54.17M
23.64%
-2.66M
2024Q4
855
52.85M
22.63%
+3.24M
2024Q3
827
49.68M
20.44%
+4.23M
2024Q2
801
45.24M
20.73%
+361.30K
2024Q1
817
44.34M
21.44%
-6.62M
2023Q4
879
44.00M
20.40%
+3.38M
2023Q3
904
40.73M
20.46%
-291.47K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
AT Impf GmbH
101.85M
40.33%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
15.89%
-304.48K
-0.75%
Mar 31, 2025
Baillie Gifford & Co.
7.88M
3.12%
-159.51K
-1.98%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.98M
1.97%
-2.00M
-28.65%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
4.83M
1.91%
+1.24M
+34.32%
Sep 30, 2025
Flossbach von Storch AG
4.23M
1.68%
-65.00
-0.00%
Sep 30, 2025
PRIMECAP Management Company
3.87M
1.53%
-130.70K
-3.27%
Sep 30, 2025
Dodge & Cox
3.65M
1.44%
+2.77M
+315.65%
Sep 30, 2025
Sahin (Ugur MD)
2.05M
0.81%
-724.50K
-26.11%
Mar 31, 2025
Pfizer Inc
1.66M
0.66%
-2.00M
-54.67%
Sep 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Langar Global HealthTech ETF
4.06%
iShares Genomics Immunology and Healthcare ETF
3.6%
First Trust NYSE Arca Biotechnology Index Fund
3.42%
Global X Genomics & Biotechnology ETF
3.11%
WisdomTree BioRevolution Fund
2.74%
Franklin Genomic Advancements ETF
2.46%
VanEck Biotech ETF
2.38%
Virtus LifeSci Biotech Products ETF
1.58%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1.01%
查看更多
Langar Global HealthTech ETF
佔比4.06%
iShares Genomics Immunology and Healthcare ETF
佔比3.6%
First Trust NYSE Arca Biotechnology Index Fund
佔比3.42%
Global X Genomics & Biotechnology ETF
佔比3.11%
WisdomTree BioRevolution Fund
佔比2.74%
Franklin Genomic Advancements ETF
佔比2.46%
VanEck Biotech ETF
佔比2.38%
Virtus LifeSci Biotech Products ETF
佔比1.58%
ProShares Ultra Nasdaq Biotechnology
佔比1.02%
Invesco Nasdaq Biotechnology ETF
佔比1.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Biontech SE的前五大股東是誰？
Biontech SE的前五大股東如下：
AT Impf GmbH持有股份：101.85M佔總股份比例：40.33%。
Medine GmbH持有股份：40.13M佔總股份比例：15.89%。
Baillie Gifford & Co.持有股份：7.88M佔總股份比例：3.12%。
Fidelity Management & Research Company LLC持有股份：4.98M佔總股份比例：1.97%。
T. Rowe Price Investment Management, Inc.持有股份：4.83M佔總股份比例：1.91%。
AT Impf GmbH持有股份：101.85M佔總股份比例：40.33%。
Medine GmbH持有股份：40.13M佔總股份比例：15.89%。
Baillie Gifford & Co.持有股份：7.88M佔總股份比例：3.12%。
Fidelity Management & Research Company LLC持有股份：4.98M佔總股份比例：1.97%。
T. Rowe Price Investment Management, Inc.持有股份：4.83M佔總股份比例：1.91%。
Biontech SE的前三大股東類型是什麼？
Biontech SE 的前三大股東類型分別是：
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.
有多少機構持有Biontech SE(BNTX)的股份？
截至2025Q4，共有774家機構持有Biontech SE的股份，合計持有的股份價值約為54.93M，占公司總股份的21.75% 。與2025Q3相比，機構持股有所增加，增幅為-3.93%。
哪個業務部門對Biontech SE的收入貢獻最大？
在FY2019，Collaboration Revenue業務部門對Biontech SE的收入貢獻最大，創收84.43M，占總收入的77.75% 。
